- Canadian among group of Grand Prize finalists who will present their ideas during a live pitch event NORTHBROOK, Ill., Sept. 30, 2019 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") today announced the finalists for its fourth annual C 3 (Changing Cancer Care) Prize, a challenge that funds the best ideas beyond medicine to improve cancer care for patients, caregivers and their loved ones....

-Total Funds To Be Awarded Increased to $200,000; All Encouraged to Apply - NORTHBROOK, Ill., May 20, 2019 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") today announced the call for entries for the fourth annual Astellas Oncology C 3 Prize (Changing Cancer Care), a challenge that funds the best non-treatment ideas to improve cancer care for patients, caregivers and their loved ones. This...

Astellas ranked 22 nd on the Best Workplaces ™ in Canada list, in addition to recognition on the 2019 lists of Best Workplaces ™ in Canada for Giving Back, Inclusion and Women MARKHAM, ON , April 29, 2019 /CNW/ - Astellas Pharma Canada, Inc. (Astellas), the Canadian subsidiary of Tokyo based Astellas Pharma, Inc., has once again been honoured as one of the Best Workplaces ™ in Canada by the Great...

MARKHAM, ON, Jan. 15, 2019 /CNW/ - Astellas Pharma Canada, Inc. is proud to announce that the Company has been named on the 2019 list of Best Workplaces™ for Inclusion. Astellas received this recognition after a thorough and independent analysis conducted by Great Place to Work®. In addition to being cited for Inclusion, Astellas was named in 2018 for the third consecutive year as a Best Workplace...

MARKHAM, ON, Jan.14, 2019 /CNW/ - Astellas Pharma Canada, Inc., today announced that Health Canada approved an expanded indication for enzalutamide, an androgen receptor inhibitor for the treatment of patients with prostate cancer, following a Priority Review by Health Canada's Therapeutic Products Directorate (TPD). With this designation, enzalutamide is now indicated to treat men with non...